This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

PATH Resources

Our online catalog indexes publications, presentations, and related resources for peers in our field.

18 Resources
18 Resources
18 Resources
    Date
  1. The Diarrhea Innovations Group (DIG) is a global network of innovators committed to reducing child mortality and morbidity from enteric and diarrheal diseases through the advancement of appropriate diagnostic and therapeutic technologies and approaches. It is a voluntary association of academic, nonprofit, public, and private members. The group aims to accelerate progress by focusing on solutions with the greatest potential for positive health impact in countries that bear the highest disease burden.
    Published: February 2019
    Type: Resource Page
  2. A summary of the work led by the Diarrhea Innovations Group, housed at PATH, to submit an application to the World Health Organization's Model List of Essential Medicines for Children for the addition of co-packaged oral rehydration solution (ORS) and zinc as an individual listing. The addition of a co-packaged listing has the potential to reinforce the lifesaving benefits of ORS and zinc in managing childhood diarrhea as a cornerstone for all health care systems involved in diarrhea management.
    Published: November 2018
    Type: Resource Page
  3. Environmental enteric dysfunction (EED) is an intestinal disorder common among children living in low-resource settings. EED is associated with increased risk of growth stunting, cognitive deficits, and reduced responsiveness to oral vaccines. This resource provides an overview of PATH's work to develop a prototype assay to quantitate multiple markers of EED, systemic inflammation, growth hormone (GH) resistance, and micronutrients for use in EED clinical research in low-resource settings.
    Published: November 2018
    Type: Resource Page
  4. Cryptosporidium is an intestinal protozoan parasite that is a major cause of diarrheal disease among young children in low-resource settings. Beyond diarrheal disease, cryptosporidiosis is associated with other chronic conditions, including growth faltering, environmental enteric dysfunction, and possibly impaired cognitive development. Current therapeutic options are limited, with only one drug, nitazoxanide, approved by the United States Food and Drug Administration. There is only one drug in clinical trials against Cryptosporidium: clofazimine, a repurposed leprosy drug developed more than three decades ago. There are no vaccines for Cryptosporidium approved or in clinical development. This poster summarizes key initiatives to develop new Cryptosporidium drugs, including an overview of PATH's portfolio.
    Published: November 2018
    Type: Resource Page
  5. PATH delivers statement at the 71st World Health Assembly on addressing the global shortage of, and access to, medicines and vaccines.
    Published: May 2018
    Type: Resource Page
Load more